Use: Labeled indications
- ZYMAXID ® is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis…
Full indications and usage US FDA label
1 INDICATIONS AND USAGE ZYMAXID ® is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group * Streptococcus oralis * Streptococcus pneumoniae Aerobic gram-negative bacteria: Haemophilus influenzae *Efficacy for these organisms were studied in fewer than 10 infections. ZYMAXID ® is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae (1)
Contraindications
4 CONTRAINDICATIONS ZYMAXID ® is contraindicated in patients with a history of hypersensitivity to gatifloxacin, to other quinolones, or to any of the components in this medication [see Warnings and Precautions (5.1)]. ZYMAXID ® is contraindicated in patients with a history of hypersensitivity to gatifloxacin, to other quinolones, or to any of the components in this medication. (4)
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
2 DOSAGE AND ADMINISTRATION Day 1: Instill one drop every two hours in the affected eye(s) while awake, up to 8 times. Day 2 through Day 7: Instill one drop two to four times daily in the affected eye(s) while awake. Day 1: Instill one drop every two hours in the affected eye(s) while awake, up to 8 times on Day 1. Days 2 through 7: Instill one drop two to four times daily in the affected eye(s) while awake on Days 2 through 7. (2)
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of ZYMAXID ® in infants below one year of age have not been established. ZYMAXID ® has been demonstrated in clinical trials to be safe and effective for the treatment of bacterial conjunctivitis in pediatric patients one year or older [see Clinical Studies (14)].
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients.
Dosage forms
Philippines
- Ophthalmic solution: 3 mg/mL
- Ophthalmic suspension: 3 mg/mL
Registered products in the Philippines
6 products registered with the Food and Drug Administration (FDA) Philippines list Gatifloxacin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products6
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AgatifloxGatifloxacin | 3 mg/mL (0.3% w/v) Ophthalmic SolutionLDPE Plastic Dropper Tipped Bottle in 5 mL ((Box of 1's)) | Rx | ASHFORD PHARMACEUTICAL LABORATORIES, INC.Philippines | Trader: SENSOMED PHILS., INC. | DR-XY42685 | Sep 27, 2028 | |
EngattGatifloxacin | 3 mg/mL (0.3% w/v) Ophthalmic SuspensionLDPE Plastic dropper bottle in 5 mL (Box of 1's) | Rx | Makcur Laboratories Ltd.India | Entod Pharmaceuticals Ltd. | DR-XY49563 | Oct 21, 2030 | |
ItifloxGatifloxacin | 3 mg/mL Ophthalmic Solution10 mL LDPE Plastic Dropper-Tipped Bottle x 5 mL (Box of 1's) | Rx | Ashford Pharmaceutical Laboratories, Inc.Philippines | Trader: Medilife Pharma, Inc. | DRP-2371 | Mar 4, 2031 | |
NoneGatifloxacin | 3 mg/ mL Ophthalmic Solution10 mL LDPE Plastic Dropper-Tipped Bottle x 5 mL (Box of 1's) | Rx | Ashford Pharmaceutical Laboratories, Inc.Philippines | Celsus Pharmaceuticals Phil., Inc.Trader: Medilife Pharma, Inc. | DRP-2371-02 | Aug 3, 2030 | |
TifloxGatifloxacin | 3mg/mL (0.3%) Ophthalmic Solution5 mL in 10 mL LDPE Plastic Bottle fitted with an LDPE Plastic Dropper Plug and an HDPE Tamper-Proof Cap in a box Box of 1's | Rx | Ashford Pharmaceutical Laboratories, Inc.Philippines | Trader: Pharmabiz Solutions, Inc. | DR-XY39387 | May 4, 2031 | |
ZymarGatifloxacin | 3 mg/mL (0.3% w/v) Ophthalmic SolutionLow Density Polyethylene (LDPE) bottle x 5 mL Box of 1's | Rx | Allergan Sales, LLCUSA | Importer: Zuellig Pharma Corporation | DR-XY30493 | Jan 28, 2030 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Ophthalmic solution: 0.5% gatifloxacin (5 mg/mL) Ophthalmic solution: 0.5% gatifloxacin (5mg/mL) (3)
Warnings/Precautions
- Hypersensitivity (5.1)
- Growth of Resistant Organisms with Prolonged Use (5.2)
- Corneal Endothelial Cell Injury (5.3)
5.1 Hypersensitivity
5.1 Hypersensitivity Some patients receiving topical ophthalmic gatifloxacin experienced hypersensitivity reactions including anaphylactic reactions, angioedema (including pharyngeal, laryngeal, or facial edema), dyspnea, urticaria, and itching, even following a single dose. Rare cases of Stevens-Johnson Syndrome were reported in association with topical ophthalmic gatifloxacin use.
If an allergic reaction to gatifloxacin occurs, discontinue the drug [see Patient Counseling Information (17)].
5.2 Growth of Resistant Organisms with Prolonged Use
5.2 Growth of Resistant Organisms with Prolonged Use Prolonged use of ZYMAXID ® may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy. Whenever clinical judgment dictates, examine the patient with the aid of magnification, such as slit lamp biomicroscopy and where appropriate, fluorescein staining. 5. 3 Corneal Endothelial Cell Injury ZYMAXID ® is for topical ophthalmic use.
ZYMAXID ® may cause corneal endothelial cell injury if introduced directly into the anterior chamber of the eye.
Adverse reactions
Adverse reactions (US label) US FDA label
6 ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling: Hypersensitivity [see Contraindications (4) and Warnings and Precautions (5.1)] Growth of Resistant Organisms With Prolonged Use [see Warnings and Precautions (5.2)] Corneal Endothelial Cell Injury [see Warnings and Precautions (5.3)] Most common adverse reactions occurring in ≥ 1 % of patients included worsening of conjunctivitis, eye irritation, dysgeusia, and eye pain. (6) To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800-433-8871 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6. 1 Clinical Studies Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
In clinical studies of patients with bacterial conjunctivitis treated with ZYMAXID ® (N=717), the most frequently reported adverse reactions occurring in ≥ 1 % of patients were: worsening of the conjunctivitis, eye irritation, dysgeusia, and eye pain. Additional adverse reactions reported with other formulations of gatifloxacin ophthalmic solution in other clinical studies included chemosis, conjunctival hemorrhage, dry eye, eye discharge, eyelid edema, headache, increased lacrimation, keratitis, red eye, papillary conjunctivitis, and reduced visual acuity. 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of ZYMAXID ® or with other formulations of gatifloxacin ophthalmic solution.
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These reactions included anaphylactic reactions and angioedema (including pharyngeal, oral or facial edema), blepharitis, dyspnea, eye pruritus, eye swelling (including corneal and conjunctival edema), hypersensitivity, including signs and symptoms of eye allergy and allergic dermatitis, nausea, pruritus (including pruritus generalized, rash, urticaria), and vision blurred.
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary There are no available data on the use of ZYMAXID ® in pregnant women to inform a drug-associated risk. Administration of oral gatifloxacin to pregnant rats and rabbits throughout organogenesis did not produce adverse development outcomes at clinically relevant doses. Administration of gatifloxacin to rats during late gestation through lactation did not produce adverse maternal, fetal or neonatal effects at clinically relevant doses.
Data Animal Data Oral administration of gatifloxacin to pregnant rats throughout organogenesis produced teratogenic effects in rat fetuses, including skeletal/craniofacial malformations, delayed ossification, atrial enlargement, and reduced fetal weight, at doses greater than or equal to 150 mg/kg/day (approximately 600-fold higher than the maximum recommended human ophthalmic dose [MRHOD] for ZYMAXID ® of 0.04 mg/kg/day, on a mg/m 2 basis). No teratogenic effects were observed in rat or rabbit fetuses at doses of gatifloxacin up to 50 mg/kg/day (approximately 200- and 400-fold higher than the MRHOD, respectively, on a mg/m 2 basis).
In a perinatal/postnatal study in rats, oral administration of gatifloxacin during late gestation through lactation produced an increase in late gestation fetal loss and neonatal/perinatal mortality at 200 mg/kg/day (approximately 800-fold higher than the MRHOD on a mg/m 2 basis).
Mechanism of action
12.1 Mechanism of Action Gatifloxacin is a quinolone antimicrobial [see Microbiology (12.4)].
US FDA labelPharmacokinetics
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Gatifloxacin ophthalmic solution 0.5% was administered to one eye of 6 healthy male subjects each in an escalated dosing regimen starting with a single 2 drop dose, then 2 drops 4 times daily for 7 days, and finally 2 drops 8 times daily for 3 days. At all time points, serum gatifloxacin levels were below the lower limit of quantification (5 ng/mL) in all subjects.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. ZYMAXID · Allergan, Inc. [US FDA-approved label, version 12, September 8, 2016]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1160b16c-929a-4e85-9c0b-1d8c96a7678b
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .